Anebulo Pharmaceuticals, Inc.

As of April 29, 2024, the trend is bullish but with mixed strength indicators, showing positive momentum on weekly and monthly MACD while daily moving averages and monthly KST suggest short-term weakness, indicating caution is advised.

Anebulo Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $60.39 million. The company has no dividends, a negative debt equity ratio, and a return on equity of -57.12%.

As of Jun 18, Anebulo Pharmaceuticals, Inc. has a market capitalization of 60.39 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -7.69 million over the last four quarters. As of Jun 24, the company's shareholder's funds were 3.81 million, and total assets were 4.07 million.